IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.020
+0.010 (0.99%)
Jul 18, 2025, 4:00 PM - Market closed
IceCure Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for IceCure Medical stock has a target of 2.5, which predicts a 145.1% increase from the current stock price of 1.02.
Price Target: $2.5 (+145.1%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 29, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for IceCure Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +145.10% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +145.10% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +145.10% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +145.10% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +145.10% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
6.04M
from 3.29M
Increased by 83.41%
Revenue Next Year
13.58M
from 6.04M
Increased by 124.95%
EPS This Year
-0.22
from -0.30
EPS Next Year
-0.17
from -0.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 29.0M | 50.1M | ||
| Avg | 6.0M | 13.6M | 48.7M | ||
| Low | 3.7M | 6.0M | 46.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 217.9% | 380.7% | 269.0% | ||
| Avg | 83.4% | 125.0% | 258.4% | ||
| Low | 10.9% | -1.0% | 244.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | -0.06 | 0.07 | ||
| Avg | -0.22 | -0.17 | 0.07 | ||
| Low | -0.24 | -0.24 | 0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.